Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

For Q1 2025, NEXGEL expects revenue of at least $2.75 million, while projecting at least $13 million in revenue for the full year 2025. The company anticipates achieving positive EBITDA in 2025.

Global IPO markets made steady gains in 2024, with IPO proceeds increasing compared to the previous year as the high interest ...

Rumours that German pharma Stada may be up for sale have been all but confirmed by the company's chief executive, who told a news agency that "exploratory talks" are taking place. Peter ...

Q4 2024 Earnings Call Transcript March 24, 2025 NEXGEL, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. Operator: Good afternoon. I will be your conference operator ...

Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior yearFull year ...

Verisure’s majority owner Hellman & Friedman has lined up more banks for a potential initial public offering of the security ...

Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year 2024 revenue totaled $8.69 million, an increase of 112 ...

NEXGEL, Inc. (NASDAQ: NXGL) has announced its fourth-quarter and full-year 2024 financial results, highlighting unprecedented ...

Stada Arzneimittel AG’s private equity owners are pushing back a planned initial public offering of the German drugmaker until September, people with knowledge of the matter said. Most Read from ...

After hours: 26 March at 19:57:27 GMT-4 Loading Chart for DB ...